Earnings call transcript: eXoZymes posts q2 2026 loss as launch plans advance
eXoZymes Inc. reported a second quarter net loss of $2.88 million on February 28, 2026. The pre-revenue biotech company ended the quarter with $5.65 million in cash and reported its first half operating expenses of $5.34 million. The company's lead product, NCT, made significant progress, with a pilot-scale campaign in March producing over 500 grams of high-purity material.
Management highlighted a 10x productivity improvement in NCT, generated through both process efficiencies and AI-enhanced biomanufacturing. The company expects to maintain sufficient liquidity to fund operations through the end of 2026. eXoZymes' shares rose 10% in regular trading to $7.04, then fell 7.5% after hours to $6.51. The company's stock is currently valued at $58.3 million, but analysts suggest it may be overvalued relative to its Fair Value estimate.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.